Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 23:28:100361.
doi: 10.1016/j.jbo.2021.100361. eCollection 2021 Jun.

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

D L Kendler  1 , J J Body  2 , M L Brandi  3 , R Broady  4 , J Cannata-Andia  5 , M J Cannata-Ortiz  6 , A El Maghraoui  7 , G Guglielmi  8 , P Hadji  9 , D D Pierroz  10 , T J de Villiers  11 , P R Ebeling  12 , R Rizzoli  13
Affiliations
Review

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

D L Kendler et al. J Bone Oncol. .

Abstract

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT.

Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture.

Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.

Keywords: Bone loss; Bone marrow; Bone mineral density; Fracture; Hematopoietic stem cell; Transplantation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Management algorithm for patients undergoing allogeneic stem cell transplant. The asterisk symbol represents patients receiving an autologous HSCT with underlying myeloma , . DXA: dual energy X-ray absorptiometry; Ca: calcium; PO4: phosphate; ALP: alkaline phosphatase; 25-OHD: 25-hydroxy vitamin D; TSH: thyroid-stimulating hormone; GVHD: graft-versus-host disease; eGFR: estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Kendler D.L., Body J.J., Brandi M.L. Bone management in hematologic stem cell transplant recipients. Osteoporos. Int. 2018;29:2597–2610. - PubMed
    1. McClune B.L., Majhail N.S. Osteoporosis after stem cell transplantation. Curr. Osteoporos. Rep. 2013;11:305–310. - PubMed
    1. Joseph R.W., Alousi A., Konda B. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am. J. Hematol. 2011;86:954–956. - PubMed
    1. Massenkeil G., Fiene C., Rosen O., Michael R., Reisinger W., Arnold R. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia. 2001;15:1701–1705. - PubMed
    1. Sproat L., Bolwell B., Rybicki L., Dean R., Sobecks R., Pohlman B., Andresen S., Sweetenham J., Copelan E., Kalaycio M. Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011;17:1079–1083. - PubMed

LinkOut - more resources